ABP-150

N/A

Report date: 2026/03/19 17:01:26

Base Information

Drug NameABP-150

Drug Alias Nameanti-CD3/anti-claudin 18.2 tetravalent bispecific T-cell engagerABP-150

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CLDN18Anti-CD3

TargetsClaudin-18 splice variant 2T cell surface glycoprotein CD3

Therapy Area/IndicationsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbpro Corp

China Registration ClassN/A

Develop Information

Active CompaniesAbpro Corp

Inactive CompaniesN/A

Active IndicationsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A